Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with a hematologic or oncologic diagnosis without morphological evidence of disease in which allogeneic HSCT is thought to be beneficial.~2. Patients must have a related donor who is a two or more allele mismatch at the HLA-A; B; C; DR loci.~3. Patients must have adequate organ function:~   1. LVEF (Left ventricular ejection fraction) of \>50%~  2. Diffusion Capacity for Carbon Monoxide (DLCO) \>50% of predicted corrected for hemoglobin~  3. Adequate liver function as defined by a serum bilirubin \<1.8, Aspartate Aminotransferase (AST) or alanine aminotransferase (ALT) \< 2.5X upper limit of normal~  4. Creatinine clearance of \> 60 ml/min~4. Performance status \> 80% (TJU Karnofsky)~5. Hematopoietic Comorbidity Index (HCT-CI) Score \< 5 Points~6. Patients must be willing to use contraception if they have childbearing potential~7. Able to give informed consent, or if decisionally impaired, have a legal next of kin or guardian that can give informed consent~Exclusion Criteria:~1. Performance status \< 80 % (TJU Karnofsky)~2. HCT-CI Score \> 5 Points~3. Combination of Performance status of \< 80% (TJU Karnofsky) and an HCT-CI of 4 points or more.~4. HIV positive~5. Active involvement of the central nervous system with malignancy~6. Psychiatric disorder that would preclude patients from signing an informed consent~7. Pregnancy~8. Patients with life expectancy of \< 6 months for reasons other than their underlying hematologic/oncologic disorder~9. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or who have recently received horse or rabbit anti-thymocyte globulin and have an ATG level of \> 2 ugm/ml~10. Patients who cannot receive cyclophosphamide~11. Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (haploidentical allogeneic HSCT) (Type: EXPERIMENTAL): Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).